大药企卖疫苗等生物制品 不再按3%简易计税

Core Viewpoint - The simplified tax policy for biological products, including vaccines, will be canceled starting this year, with a transition to general tax calculation methods by 2026, impacting the tax burden on related enterprises [1][2][3]. Group 1: Tax Policy Changes - The simplified tax rate of 3% for biological products will no longer apply from this year, as stated in the recent announcement by the Ministry of Finance and the State Administration of Taxation [1][2]. - From January 1, 2026, general taxpayers selling biological products will need to determine applicable tax rates based on specific product types, moving away from the simplified tax method [2][3]. - The announcement specifies that the simplified tax policy for biological products will cease, aligning with the broader changes in the VAT law [1][3]. Group 2: Impact on Enterprises - The cancellation of the simplified tax policy may lead to increased tax burdens for some biological product enterprises, particularly those with insufficient input tax credits [5]. - Companies with well-established supply chains and sufficient input tax deductions may see a balanced or reduced tax burden under the general tax method [5]. - Enterprises are advised to reassess their supplier and customer relationships and adjust pricing strategies to adapt to the new tax policy [5][6]. Group 3: Retained Tax Benefits - Certain biological products, such as anti-cancer drugs and rare disease medications, will continue to benefit from the 3% simplified tax rate until December 31, 2027 [6]. - The announcement outlines four specific policies that will remain effective for these products, ensuring continued support for critical healthcare needs [6].